Eli Lilly has announced that it will sell higher doses of its weight-loss drug Zepbound directly to consumers on its website, starting in August. The 12.5 and 15-milligram doses will be priced at $499 a month or less, making all doses available without insurance. This comes as a response to the high demand for weight-loss medications and limited insurance coverage. The injectable Zepbound, a GLP-1 receptor agonist, aims to treat obesity alongside other medical issues. Lilly aims to increase accessibility to these medications, reflecting the seriousness of obesity as a chronic disease.
"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, emphasizing the importance of medication access.
"Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound," noted Pacheco.
Collection
[
|
...
]